Cargando…
Canadian ENHANCE data support the efficacy and safety of drotrecogin alfa (activated) despite higher disease severity than the global ENHANCE population
Autores principales: | Hall, R, Fisher, H, Marshall, J, Hodder, R, Russell, J, Lee, B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4098344/ http://dx.doi.org/10.1186/cc3257 |
Ejemplares similares
-
Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort
por: Hodder, Richard V, et al.
Publicado: (2009) -
The safety profile of drotrecogin alfa (activated)
por: Fumagalli, Roberto, et al.
Publicado: (2007) -
Extended drotrecogin alfa (activated) therapy in patients with persistent requirement for vasopressor support after 96-hour infusion with commercial drotrecogin alfa (activated)
por: Dhainaut, J, et al.
Publicado: (2008) -
Practical aspects of treatment with drotrecogin alfa (activated)
por: Camporota, Luigi, et al.
Publicado: (2007) -
Introduction: severe sepsis and drotrecogin alfa (activated)
por: Artigas, Antonio, et al.
Publicado: (2007)